DEX-GATI Trademark

Trademark Overview

On Thursday, February 9, 2017, a trademark application was filed for DEX-GATI with the United States Patent and Trademark Office. The USPTO has given the DEX-GATI trademark a serial number of 87329838. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Wednesday, December 12, 2018. This trademark is owned by IMPRIMIS PHARMACEUTICALS, INC.. The DEX-GATI trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical compositions for ophthalmological use
dex-gati

General Information

Serial Number87329838
Word MarkDEX-GATI
Filing DateThursday, February 9, 2017
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateWednesday, December 12, 2018
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesPharmaceutical compositions for ophthalmological use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, February 14, 2017
Primary Code005
First Use Anywhere DateWednesday, February 1, 2017
First Use In Commerce DateWednesday, February 1, 2017

Trademark Owner History

Party NameIMPRIMIS PHARMACEUTICALS, INC.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92130

Trademark Events

Event DateEvent Description
Wednesday, December 12, 2018ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Wednesday, December 12, 2018ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Thursday, May 17, 2018NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED
Wednesday, May 16, 2018NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, May 16, 2018NON-FINAL ACTION E-MAILED
Wednesday, May 16, 2018NON-FINAL ACTION WRITTEN
Wednesday, May 16, 2018USE AMENDMENT ACCEPTED
Saturday, May 12, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, May 11, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, May 11, 2018TEAS REQUEST FOR RECONSIDERATION RECEIVED
Saturday, May 12, 2018AMENDMENT TO USE PROCESSING COMPLETE
Saturday, May 12, 2018USE AMENDMENT FILED
Friday, May 11, 2018TEAS AMENDMENT OF USE RECEIVED
Tuesday, December 5, 2017NOTIFICATION OF FINAL REFUSAL EMAILED
Tuesday, December 5, 2017FINAL REFUSAL E-MAILED
Tuesday, December 5, 2017FINAL REFUSAL WRITTEN
Friday, November 17, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, November 17, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, November 15, 2017ASSIGNED TO LIE
Friday, November 3, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, May 8, 2017NOTIFICATION OF PRIORITY ACTION E-MAILED
Monday, May 8, 2017PRIORITY ACTION E-MAILED
Monday, May 8, 2017PRIORITY ACTION WRITTEN
Wednesday, May 3, 2017ASSIGNED TO EXAMINER
Tuesday, February 14, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, February 13, 2017NEW APPLICATION ENTERED IN TRAM

Related Keywords

gati ophthalmological compositions pharmaceutical